Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Daria A. Filonenko"'
Publikováno v:
Современная онкология, Vol 26, Iss 2, Pp 182-189 (2024)
The classification of breast cancer (BC) by immunohistochemical phenotypes is widely used in routine clinical practice. However, the genetic profile of the tumor does not always correspond to the pathomorphological one, which can significantly affect
Externí odkaz:
https://doaj.org/article/9bd059acb1804b48b14f790646bef706
Autor:
Elena N. Yushchuk, Elizaveta G. Medvedeva, Daria A. Filonenko, Svetlana V. Ivanova, Liudmila G. Zhukova, Daria A. Sapunova
Publikováno v:
Терапевтический архив, Vol 95, Iss 8, Pp 621-626 (2023)
Background. Modern breast cancer chemotherapy regimens (BC) consider individual patient parameters and ranges of cardiotoxic doses. However, clinicians often record clinical and laboratory-instrumental signs of cardio- and vasculotoxicity in patients
Externí odkaz:
https://doaj.org/article/a52888df66f145b2bdfe73a8d65a0a3d
Autor:
Katerina S. Grechukhina, Karina A. Vorontsova, Daria A. Filonenko, Pavel S. Tyutyunnik, Victoria V. Shchadrova, Liudmila G. Zhukova
Publikováno v:
Современная онкология, Vol 24, Iss 3, Pp 373-379 (2022)
Metastatic luminal B HER2-negative breast cancer (HR+/HER2- mBC) occupies a leading place in the global structure of morbidity and mortality among women. The current gold standard of first-line treatment is the combination of CDK4/6 inhibitors with a
Externí odkaz:
https://doaj.org/article/e339e930f9864adeba2b3549e8696fc5
Autor:
Irena L. Shlivko, Oxana E. Garanina, Elena V. Artamonova, Inna P. Ganshina, Liudmila G. Zhukova, Irina A. Koroleva, Anna V. Michenko, Tatiana Yu. Semiglazova, Daria A. Filonenko
Publikováno v:
Современная онкология, Vol 23, Iss 4, Pp 572-576 (2021)
The consensus on the prevention and correction of rash in patients with HR+ HER2- metastatic breast cancer treated with alpelisib was developed by the experts of the Russian Society of Clinical Oncology and dermatovenerologists. PIK3CA mutation is a
Externí odkaz:
https://doaj.org/article/4cf9483c4ddd4123abe0816e579c40c6
Publikováno v:
Современная онкология, Vol 22, Iss 4, Pp 96-100 (2021)
We have three drugs for treatment of gastrointestinal stromal tumors (GIST): imatinib, sunitinib and regorafenib. Avapritinib (Ayvakit, BLU-285) is one more drug that was approved in January 2020. Avapritinib is a new selective tyrosine kinase inhibi
Externí odkaz:
https://doaj.org/article/6e46ed6345224af8a1b117b56a28b0d7
Autor:
Daria A. Filonenko, Andrey A. Meshcheryakov, Petr P. Arkhiri, Maxim P. Nikulin, Evgeniia S. Kolobanova
Publikováno v:
Современная онкология, Vol 22, Iss 2, Pp 133-136 (2020)
Succinate dehydrogenase deficient gastrointestinal stromal tumors (dSDH GIST) is a unique group of GISTs with an energy metabolism defect as the key oncogenic mechanism without mutations in the proto-oncogene receptor tyrosine kinase (KIT) and platel
Externí odkaz:
https://doaj.org/article/553e488d924d466a9a73765baf3532ec
Publikováno v:
Современная онкология, Vol 22, Iss 4, Pp 96-100 (2021)
We have three drugs for treatment of gastrointestinal stromal tumors (GIST): imatinib, sunitinib and regorafenib. Avapritinib (Ayvakit, BLU-285) is one more drug that was approved in January 2020. Avapritinib is a new selective tyrosine kinase inhibi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cfa04643042f80496d8cd9b45f8f267
https://modernonco.orscience.ru/1815-1434/article/viewFile/61163/44252
https://modernonco.orscience.ru/1815-1434/article/viewFile/61163/44252
Autor:
Andrey A. Meshcheryakov, Daria A. Filonenko, Evgeniia S. Kolobanova, M P Nikulin, Petr P. Arkhiri
Publikováno v:
Современная онкология, Vol 22, Iss 2, Pp 133-136 (2020)
Succinate dehydrogenase deficient gastrointestinal stromal tumors (dSDH GIST) is a unique group of GISTs with an energy metabolism defect as the key oncogenic mechanism without mutations in the proto-oncogene receptor tyrosine kinase (KIT) and platel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c070f0bb897f2ab4048b4f84fd044b0b
https://doi.org/10.26442/18151434.2020.2.200053
https://doi.org/10.26442/18151434.2020.2.200053